dbacp00753
General Description
Peptide name : 9S1R
Source/Organism : Not found
Linear/Cyclic : Linear
Chirality : L
Sequence Information
Sequence : RRRRRWCMNW
Peptide length: 10
C-terminal modification: Linear
N-terminal modification : Free
Non-natural peptide information: None
Activity Information
Assay type : MTT/MTS assay
Assay time : 24h
Activity : IC50 : 9 µM
Cell line : LNCaP
Cancer type : Prostate cancer
Other activity : Not found
Physicochemical Properties
Amino acid composition bar chart :
Molecular mass : 1519.8051 Dalton
Aliphatic index : 0
Instability index : 317.63
Hydrophobicity (GRAVY) : -2.34
Isoelectric point : 12
Charge (pH 7) : 4.7502
Aromaticity : 0.2
Molar extinction coefficient (cysteine, cystine): (11000, 11000)
Hydrophobic/hydrophilic ratio : 0.66666666
hydrophobic moment : -0.367
Missing amino acid : H,Q,T,P,I,E,K,S,D,Y,F,L,A,V,G
Most occurring amino acid : R
Most occurring amino acid frequency : 5
Least occurring amino acid : C
Least occurring amino acid frequency : 1
Structural Information
3D structure :
Secondary structure fraction (Helix, Turn, Sheet): (0.1, 0.1, 0.2)
SMILES Notation: CSCC[C@H](NC(=O)[C@H](CS)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O
Secondary Structure :
| Method | Prediction |
|---|---|
| GOR | HHHHTTEETT |
| Chou-Fasman (CF) | CCEECCCCCC |
| Neural Network (NN) | CCCHHHHCCC |
| Joint/Consensus | CCCCCCCCCC |
Molecular Descriptors and ADMET Properties
Molecular Descriptors: Click here to download
ADMET Properties: Click here to download
Cross Referencing databases
Reference
1 : Alileche A, et al. Nullomer derived anticancer peptides (NulloPs): differential lethal effects on normal and cancer cells in vitro. Peptides. 2012; 38:302-11. doi: 10.1016/j.peptides.2012.09.015
Literature
Paper title : Nullomer derived anticancer peptides (NulloPs): differential lethal effects on normal and cancer cells in vitro.
Doi : https://doi.org/10.1016/j.peptides.2012.09.015
Abstract : We demonstrate the first use of the nullomer (absent sequences) approach to drug discovery and development. Nullomers are the shortest absent sequences determined in a species, or group of species. By identifying the shortest absent peptide sequences from the NCBI databases, we screened several potential anti-cancer peptides. In order to improve cell penetration and solubility we added short poly arginine tails (5Rs), and initially solubilized the peptides in 1M trehalose. The results for one of the absent sequences 9R (RRRRRNWMWC), and its scrambled version 9S1R (RRRRRWCMNW) are reported here. We refer to these peptides derived from nullomers as PolyArgNulloPs. A control PolyArgNulloP, 124R (RRRRRWFMHW), was also included. The lethal effects of 9R and 9S1R are mediated by mitochondrial impairment as demonstrated by increased ROS production, ATP depletion, cell growth inhibition, and ultimately cell death. These effects increase over time for cancer cells with a concomitant drop in IC-50 for breast and prostate cancer cells. This is in sharp contrast to the effects in normal cells, which show a decreased sensitivity to the NulloPs over time.